Amarin Corp Plcuk (AMRN) Shares Outstanding (Diluted Average) (2010 - 2025)
Amarin Corp Plcuk (AMRN) reported Shares Outstanding (Diluted Average) of $413.4 million for Q1 2025, up 0.8% year-over-year from $410.1 million in Q1 2024, and up 0.8% quarter-over-quarter from $410.1 million in Q1 2024.
Amarin Corp Plcuk (AMRN) Shares Outstanding (Diluted Average) (2010 - 2025) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 14 years of Shares Outstanding (Diluted Average) data on file, last reported at $413.4 million in Q1 2025.
- Shares Outstanding (Diluted Average) for Q1 2025 came in at $413.4 million, up 0.8% year-over-year; the trailing twelve-month figure through Mar 2025 was $413.4 million (up 0.8% YoY), and the FY2020 annual result was $381.8 million, up 11.45% from the prior year.
- Shares Outstanding (Diluted Average) climbed to $413.4 million in Q1 2025 per AMRN's latest filing, from $410.1 million in the prior quarter.
- Over five years, Shares Outstanding (Diluted Average) peaked at $413.4 million in Q1 2025 and troughed at $394.6 million in Q1 2021.
- A 4-year average of $402.3 million and a median of $397.8 million in 2022 frame the typical range for Shares Outstanding (Diluted Average).
- The sharpest annual moves came in 2021 and 2025: Shares Outstanding (Diluted Average) climbed 9.28% in 2021, then climbed 0.8% in 2025.
- A 4-year view of Shares Outstanding (Diluted Average) shows it stood at $395.7 million in 2021, then climbed by 0.54% to $397.8 million in 2022, then increased by 3.1% to $410.1 million in 2024, then grew by 0.8% to $413.4 million in 2025.
- Business Quant data shows AMRN's Shares Outstanding (Diluted Average) at $413.4 million in Q1 2025, $410.1 million in Q1 2024, and $397.8 million in Q1 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 895.90 Mn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 2.45 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 1.77 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 544.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.25 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 5.73 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 413.42 Mn |
| Mar 31, 2024 | 410.15 Mn |
| Mar 31, 2022 | 397.81 Mn |
| Sep 30, 2021 | 395.68 Mn |
| Mar 31, 2021 | 394.64 Mn |
| Dec 31, 2020 | 381.76 Mn |
| Sep 30, 2020 | 389.70 Mn |
| Mar 31, 2020 | 361.14 Mn |
| Dec 31, 2019 | 342.54 Mn |
| Sep 30, 2019 | 336.94 Mn |
| Jun 30, 2019 | 329.79 Mn |
| Mar 31, 2019 | 328.71 Mn |
| Dec 31, 2018 | 297.24 Mn |
| Sep 30, 2018 | 295.60 Mn |
| Jun 30, 2018 | 289.46 Mn |
| Mar 31, 2018 | 285.21 Mn |
| Dec 31, 2017 | 270.65 Mn |
| Sep 30, 2017 | 270.57 Mn |
| Jun 30, 2017 | 270.73 Mn |
| Mar 31, 2017 | 270.16 Mn |